EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Sunesis Pharmaceuticals, Inc.
July 24 2015 - 7:05PM
Business Wire
The Rosen Law Firm, a global investor rights law firm, announces
it is investigating potential securities claims on behalf of
investors of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) resulting
from allegations that Sunesis Pharmaceuticals may have issued
materially misleading business information to the investing
public.
On July 23, 2015, Sunesis Pharmaceuticals disclosed that the
Food and Drug Administration would not support the filing of a New
Drug Application for its proposed leukemia
treatment—vosaroxin—because it did not reach statistical
significance on the protocol-defined primary analysis of overall
survival. On this news, shares of Sunesis Pharmaceuticals fell
$2.51 per share or over 70% on July 24, 2015, damaging
investors.
The Rosen Law Firm is preparing a class action lawsuit to
recover losses suffered by Sunesis Pharmaceuticals investors. If
you purchased shares of Sunesis Pharmaceuticals on or before July
23, 2015, please visit the firm’s website at
http://rosenlegal.com/cases-679.html for more information. You may
also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law
Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com
or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150724005894/en/
The Rosen Law Firm, P.A.Laurence Rosen, Esq.Phillip Kim,
Esq.Kevin Chan, Esq.275 Madison Avenue, 34th FloorNew York, NY
10016Tel: 212-686-1060Toll Free: 866-767-3653Fax:
212-202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024